Skip to content

Discontinued — last reported Q3 '19

Gross Profit at other companies

LQD
Liquidia CorporationLQDA
$1.6M+6.5%
ALN
Alnylam PharmaceuticalsALNY
$959.66M+83.1%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$8.07B-1.2%
Revvity logo
RevvityRVTY
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS

Other financials

Income statement

See full
Revenue$51.7M+14.1%
Operating income$17.4M+148%
Net income-$13.3M+68.6%
EPS (diluted)-$0.67+69.7%

Balance sheet

See full
Cash & equivalents$115.1M+140%
Total debt$5.1M+14.2%
Total equity$997.3M+25.4%
Total assets$1.5B+69.2%

Cash flow

See full
Operating cash flow$48.7M+291%
CapEx$228.0K+6.5%
Free cash flow$48.5M+289%

Valuation

See full
Market cap$5.51B+96.7%
Enterprise value$5.4B+95.4%
P/E35.9×
P/S20.1×+4.6×

Profitability

See full
Gross margin91.9%
Operating margin34.5%+23.0pp
Net margin55.9%+35.7pp
FCF margin44.8%+16.8pp

Returns & leverage

See full
Return on equity17.1%+11.5pp
Debt / equity0.0×
Current ratio21.3×+16.0×

Where this comes from

Calculated from Ligand Pharmaceuticals’s reported figures.

The official record: Ligand Pharmaceuticals’s 10-K, filed February 24, 2021, on SEC EDGAR. View the filing →

Questions, answered.

What does gross profit mean?
Revenue minus cost of revenue — the profit available to cover operating expenses, representing the company's pricing power and production efficiency.